Seattle/Millennium partner with Ventana for diagnostic to expand Adcetris market
This article was originally published in Scrip
Executive Summary
Seattle Genetics and Takeda's oncology subsidiary Millennium are collaborating with Roche's diagnostics company Ventana Medical Systems to develop a molecular companion diagnostic for the pharmaceutical partners' antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin).